Angiotech's resorbable sutures:
This article was originally published in Clinica
Angiotech Pharmaceuticals has received 510(k) clearance from the US FDA for its resorbable sutures product line - Quill SRS Monoderm. The products, part of the company's larger "Quill" range of self-retaining system (SRS) sutures, are made from a rapidly absorbing polymer, and are indicated for use primarily in superficial wound closure. The Vancouver, Canada firm hopes to launch the product line in the US this autumn. The Quill SRS range of sutures incorporates a patented helical barbed design which obviates the need to tie knots to hold sutures in place. Angiotech also gained 510(k) clearance to market additional diameters of its Quill SRS Polydioxanone (PDO) product line - longer-lasting absorbable sutures typically used for deeper tissue closure.
You may also be interested in...
Pain relief product sales grew 27% and upper respiratory sales 35% for the week ended 7 March as consumers respond to COVID-19, according to Nielsen data noted in a Jefferies report on consumer health purchasing trends. Private label market share is up slightly, while OTC purchases continue primarily in conventional stores.
Managing partner Corey Goodman said venBio didn’t have trouble closing its fund, because the venture capital firm prepared its investors for an economic downturn months ago.
The US FDA has proposed moving two categories of hepatitis C diagnostics to class II from class III because they pose relatively low risk.